NuView Life Sciences, Inc. is a biotechnology company based in Park City, Utah, focused on precision cancer diagnostics and therapeutics that will improve patient outcomes and reduce healthcare costs. NuView’s leading technology, NV‐VPAC1 consists of a series of peptide analogs that target the vasoactive intestinal peptide receptor type 1 (VPAC1). The VPAC1 receptor becomes overexpressed in certain key malignancies including breast, prostate, colon, bladder, and endometrial cancer. Attaching a molecular imaging or therapeutic component to a NV‐VPAC1 peptide enables NuView to develop a series of precisely targeted products that may be used in the diagnosis and treatment of cancer. The Company is currently developing the NV‐VPAC1 technology as ● a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer by combining a NV‐VPAC1 peptide with Copper‐64 ● an in vitro diagnostic kit by attaching a fluorophore to a NV‐VPAC1 peptide that may be used for detecting shed prostate and bladder cancer cells in voided urine ● a platform for the targeted delivery of anti‐cancer agents including cytotoxics and therapeutic isotopes such as Copper‐67 NuView Life Sciences has two wholly‐owned, independently operating subsidiaries: (1) NuView Diagnostics LLC that develops the liquid biopsy diagnostic applications including the in vitro prostate cancer urine screen kit and (2) US Radiopharmaceuticals Corporation, an FDA‐registered manufacturer and distributor facility of medical isotopes.